Degradation of the endothelial glycocalyx in clinical settings: Searching for the sheddases

British Journal of Clinical Pharmacology

Volumn 80, Issue 3, 2015, Pages 389-402

  Becker, Bernhard F ^a   Jacob, Matthias ^b   Leipert, Stephanie ^a   Salmon, Andrew H J ^c   Chappell, Daniel ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Urologische Klinik   (Germany)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

diabetes; inflammation; ischaemia; protease; renal failure; sepsis

Indexed keywords

CATHEPSIN B; HEPARANASE; HYALURONIC ACID; METALLOPROTEINASE; MYELOBLASTIN; SULODEXIDE; SYNDECAN; ANTIINFLAMMATORY AGENT; ENZYME INHIBITOR; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; PEPTIDE HYDROLASE; SERUM ALBUMIN;

ARTICLE; BIODEGRADATION; BLOOD VESSEL WALL; CELL MEMBRANE; GLYCOCALYX; HUMAN; HYDRAULIC CONDUCTIVITY; LEUKOCYTE; MAST CELL; PERMEABILITY BARRIER; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ADHESION; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; RENAL INSUFFICIENCY; REPERFUSION INJURY; SEPSIS; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GLYCOCALYX; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; HYALURONIC ACID; PEPTIDE HYDROLASES; RENAL INSUFFICIENCY; REPERFUSION INJURY; SEPSIS; SERUM ALBUMIN; SYNDECANS;

EID: 84940446505     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12629     Document Type: Article

References (155)

1. Pries AR, Secomb TW, Gaehtgens P,. The endothelial surface layer. Pflugers Archiv: Eur J Physiol 2000; 440: 653-66.
2. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M,. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc Res 2010; 87: 300-10.
3. Jacob M, Chappell D, Stoeckelhuber M, Welsch U, Rehm M, Bruegger D, Kaczmarek I, Conzen P, Becker BF,. Perspectives in microvascular fluid handling: does the distribution of coagulation factors in human myocardium comply with plasma extravasation in venular coronary segments? J Vasc Res 2011; 48: 219-26.
4. Vink H, Duling BR,. Capillary endothelial surface layer selectively reduces plasma solute distribution volume. Am J Physiol Heart Circ Physiol 2000; 278: H285-9.
5. Weinbaum S, Tarbell JM, Damiano ER,. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 2007; 9: 121-67.
6. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Archiv: Eur J Physiol 2007; 454: 345-59.
7. Chappell D, Jacob M, Paul O, Rehm M, Welsch U, Stoeckelhuber M, Conzen P, Becker BF,. The glycocalyx of the human umbilical vein endothelial cell: an impressive structure ex vivo but not in culture. Circ Res 2009; 104: 1313-7.
8. Jacob M, Rehm M, Loetsch M, Paul JO, Bruegger D, Welsch U, Conzen P, Becker BF,. The endothelial glycocalyx prefers albumin for evoking shear stress-induced, nitric oxide-mediated coronary dilatation. J Vasc Res 2007; 44: 435-43.
9. Curry FE, Adamson RH,. Endothelial glycocalyx: permeability barrier and mechanosensor. Ann Biomed Eng 2012; 40: 828-39.
10. Jacob M, Bruegger D, Rehm M, Stoeckelhuber M, Welsch U, Conzen P, Becker BF,. The endothelial glycocalyx affords compatibility of Starling's principle and high cardiac interstitial albumin levels. Cardiovasc Res 2007; 73: 575-86.
11. Rehm M, Zahler S, Lotsch M, Welsch U, Conzen P, Jacob M, Becker BF,. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology 2004; 100: 1211-23.
12. Adamson RH, Lenz JF, Zhang X, Adamson GN, Weinbaum S, Curry FE,. Oncotic pressures opposing filtration across non-fenestrated rat microvessels. J Physiol 2004; 557: 889-907.
13. Levick JR, Michel CC,. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res 2010; 87: 198-210.
14. Mulivor AW, Lipowsky HH,. Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol 2002; 283: H1282-91.
15. Vink H, Constantinescu AA, Spaan JA,. Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion. Circulation 2000; 101: 1500-2.
16. Chappell D, Dorfler N, Jacob M, Rehm M, Welsch U, Conzen P, Becker BF,. Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion. Shock 2010; 34: 133-9.
17. Chappell D, Heindl B, Jacob M, Annecke T, Chen C, Rehm M, Conzen P, Becker BF,. Sevoflurane reduces leukocyte and platelet adhesion after ischemia-reperfusion by protecting the endothelial glycocalyx. Anesthesiology 2011; 115: 483-91.
18. Chappell D, Brettner F, Doerfler N, Jacob M, Rehm M, Bruegger D, Conzen P, Jacob B, Becker BF,. Protection of glycocalyx decreases platelet adhesion after ischaemia/reperfusion: an animal study. Eur J Anaesth 2014; 31: 474-81.
19. Reitsma S, Oude Egbrink MG, Heijnen VV, Megens RT, Engels W, Vink H, Slaaf DW, van Zandvoort MA,. Endothelial glycocalyx thickness and platelet-vessel wall interactions during atherogenesis. Thromb Haemost 2011; 106: 939-46.
20. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S, Bernfield M,. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Gen 2000; 25: 329-32.
21. Gotte M., Syndecans in inflammation. FASEB J 2003; 17: 575-91.
22. Li S, Pettersson US, Hoorelbeke B, Kolaczkowska E, Schelfhout K, Martens E, Kubes P, Van Damme J, Phillipson M, Opdenakker G,. Interference with glycosaminoglycan-chemokine interactions with a probe to alter leukocyte recruitment and inflammation in vivo. PLoS One 2014; 9: e104107.
23. Yu WH, Woessner JF, Jr., Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem 2000; 275: 4183-91.
24. Yu WH, Yu S, Meng Q, Brew K, Woessner JF, Jr., TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275: 31226-32.
25. Gotte M, Echtermeyer F,. Syndecan-1 as a regulator of chemokine function. Scie World J 2003; 3: 1327-31.
26. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, Chappell D, Stoeckelhuber M, Welsch U, Reichart B, Peter K, Becker BF,. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007; 116: 1896-906.
27. Becker BF, Chappell D, Jacob M,. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol 2010; 105: 687-701.
28. Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, Conzen P, Becker BF,. TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol 2009; 104: 78-89.
29. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR,. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011; 254: 194-200.
30. Ostrowski SR, Berg RM, Windelov NA, Meyer MA, Plovsing RR, Moller K, Johansson PI,. Coagulopathy, catecholamines, and biomarkers of endothelial damage in experimental human endotoxemia and in patients with severe sepsis: a prospective study. J Crit Care 2013; 28: 586-96.
31. Mulivor AW, Lipowsky HH,. Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 2004; 286: H1672-80.
32. Salmon AH, Satchell SC,. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Path 2012; 226: 562-74.
33. Salmon AH, Ferguson JK, Burford JL, Gevorgyan H, Nakano D, Harper SJ, Bates DO, Peti-Peterdi J,. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 2012; 23: 1339-50.
34. Henry CB, Duling BR,. TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 2000; 279: H2815-23.
35. Padberg JS, Wiesinger A, di Marco GS, Reuter S, Grabner A, Kentrup D, Lukasz A, Oberleithner H, Pavenstadt H, Brand M, Kumpers P,. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014; 234: 335-43.
36. Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB, Kastelein JJ, Stroes ES, Vink H,. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006; 55: 1127-32.
37. Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Holleman F, Hoekstra JB, Vink H, Kastelein JJ, Stroes ES,. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55: 480-6.
38. Zuurbier CJ, Demirci C, Koeman A, Vink H, Ince C,. Short-term hyperglycemia increases endothelial glycocalyx permeability and acutely decreases lineal density of capillaries with flowing red blood cells. J Appl Physiol 2005; 99: 1471-6.
39. Nieuwdorp M, Holleman F, de Groot E, Vink H, Gort J, Kontush A, Chapman MJ, Hutten BA, Brouwer CB, Hoekstra JB, Kastelein JJ, Stroes ES,. Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia 2007; 50: 1288-93.
40. van den Berg BM, Nieuwdorp M, Stroes ES, Vink H,. Glycocalyx and endothelial (dys) function: from mice to men. Pharmacol Rep 2006; 58 Suppl: 75-80.
41. Boels MG, Lee DH, van den Berg BM, Dane MJ, van der Vlag J, Rabelink TJ,. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome. Eur J Int Med 2013; 24: 503-9.
42. Savery MD, Jang JX, Park PW, Damiano ER,. The endothelial glycocalyx in syndecan-1 deficient mice. Microvasc Res 2013; 87: 83-91.
43. Voyvodic PL, Min D, Liu R, Williams E, Chitalia V, Dunn AK, Baker AB,. Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem 2014; 289: 9547-59.
44. Hofmann-Kiefer KF, Chappell D, Knabl J, Frank HG, Martinoff N, Conzen P, Becker BF, Rehm M,. Placental syncytiotrophoblast maintains a specific type of glycocalyx at the fetomaternal border: the glycocalyx at the fetomaternal interface in healthy women and patients with HELLP syndrome. Reprod Sci 2013; 20: 1237-45.
45. Hofmann-Kiefer KF, Knabl J, Martinoff N, Schiessl B, Conzen P, Rehm M, Becker BF, Chappell D,. Increased serum concentrations of circulating glycocalyx components in HELLP syndrome compared to healthy pregnancy: an observational study. Reprod Sci 2013; 20: 318-25.
46. Osmers RG, Schutz E, Diedrich F, Wehry B, Krauss T, Oellerich M, Kuhn W,. Increased serum levels of hyaluronic acid in pregnancies complicated by preeclampsia or hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Obstet Gynecol 1998; 178: 341-5.
47. Berg S, Engman A, Holmgren S, Lundahl T, Laurent TC,. Increased plasma hyaluronan in severe pre-eclampsia and eclampsia. Scand J Clin Lab Invest 2001; 61: 131-7.
48. Stafford-Smith M, Lefrak EA, Qazi AG, Welsby IJ, Barber L, Hoeft A, Dorenbaum A, Mathias J, Rochon JJ, Newman MF, Members of the Global Perioperative Research Group. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005; 103: 229-40.
49. Battelli MG, Bolognesi A, Polito L,. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta 2014; 1843: 1502-17.
50. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F,. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
51. Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE,. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A 2013; 110: 17838-43.
52. Dallinga-Thie GM, Franssen R, Mooij HL, Visser ME, Hassing HC, Peelman F, Kastelein JJ, Péterfy M, Nieuwdorp M,. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010; 211: 1-8.
53. Kersten S., Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 2014; 184: 919-33.
54. Sarrazin S, Lamanna WC, Esko JD,. Heparan sulphate proteoglycans. Cold Spring Harb Perspect Biol 2011; 3: a004952
55. Becker BF,. Towards the physiological function of uric acid. Free Radic Biol Med 1993; 14: 615-31.
56. Bruegger D, Brettner F, Rossberg I, Nussbaum C, Kowalski C, Januszewska K, Becker BF, Chappell D,. Acute degradation of the endothelial glycocoalyx in infants undergoing cardiac surgical procedures. Ann Thorac Surg 2015; 99: 926-31.
57. Grundmann S, Fink K, Rabadzhieva L, Bourgeois N, Schwab T, Moser M, Bode C, Busch HJ,. Perturbation of the endothelial glycocalyx in post cardiac arrest syndrome. Resuscitation 2012; 83: 715-20.
58. Massoudy P, Zahler S, Barankay A, Becker BF, Richter JA, Meisner H,. Sodium nitroprusside during coronary artery bypass grafting: evidence for an antiinflammatory action. Ann Thorac Surg 1999; 67: 1059-64.
59. Massoudy P, Zahler S, Freyholdt T, Henze R, Barankay A, Becker BF, Braun SL, Meisner H,. Sodium nitroprusside in patients with compromised left ventricular function undergoing coronary bypass: reduction of cardiac proinflammatory substances. J Thorac Cardiovasc Surg 2000; 119: 566-74.
60. Massoudy P, Zahler S, Becker BF, Braun SL, Barankay A, Meisner H,. Evidence for inflammatory responses of the lungs during coronary artery bypass grafting with cardiopulmonary bypass. Chest 2001; 119: 31-6.
61. Zahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF,. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass. Cardiovasc Res 1999; 41: 722-30.
62. Annecke T, Fischer J, Hartmann H, Tschoep J, Rehm M, Conzen P, Sommerhoff CP, Becker BF,. Shedding of the coronary endothelial glycocalyx: effects of hypoxia/reoxygenation vs ischaemia/reperfusion. Br J Anaesth 2011; 107: 679-86.
63. Becker BF, Fischer J, Hartmann H, Chen CC, Sommerhoff CP, Tschoep J, Conzen PC, Annecke T,. Inosine, not adenosine, initiates endothelial glycocalyx degradation in cardiac ischemia and hypoxia. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1161-7.
64. Becker BF,. All because of the mast cell: blocking the angiotensin receptor-1 should be better than inhibiting ACE (theoretically). Cardiovasc Res 2011; 92: 7-9.
65. Chappell D, Jacob M, Rehm M, Stoeckelhuber M, Welsch U, Conzen P, Becker BF,. Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx. Biol Chem 2008; 389: 79-82.
66. Gilles S, Zahler S, Welsch U, Sommerhoff CP, Becker BF,. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res 2003; 60: 608-16.
67. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, Investigators A-I,. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.
68. Miura T, Miki T,. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008; 103: 501-13.
69. Bruegger D, Rehm M, Abicht J, Paul JO, Stoeckelhuber M, Pfirrmann M, Reichart B, Becker BF, Christ F,. Shedding of the endothelial glycocalyx during cardiac surgery: on-pump versus off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2009; 138: 1445-7.
70. Bruegger D, Schwartz L, Chappell D, Jacob M, Rehm M, Vogeser M, Christ F, Reichart B, Becker BF,. Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery. Basic Res Cardiol 2011; 106: 1111-21.
71. Svennevig K, Hoel T, Thiara A, Kolset S, Castelheim A, Mollnes T, Brosstad F, Fosse E, Svennevig J,. Syndecan-1 plasma levels during coronary artery bypass surgery with and without cardiopulmonary bypass. Perfusion 2008; 23: 165-71.
72. Maksimenko AV, Turashev AD,. No-reflow phenomenon and endothelial glycocalyx of microcirculation. Biochem Res Int 2012; 2012: 859231.
73. Bruegger D, Jacob M, Rehm M, Loetsch M, Welsch U, Conzen P, Becker BF,. Atrial natriuretic peptide induces shedding of endothelial glycocalyx in coronary vascular bed of guinea pig hearts. Am J Physiol Hear Circ Physiol 2005; 289: H1993-9.
74. Jacob M, Saller T, Chappell D, Rehm M, Welsch U, Becker BF,. Physiological levels of A-, B- and C-type natriuretic peptide shed the endothelial glycocalyx and enhance vascular permeability. Basic Res Cardiol 2013; 108: 347.
75. Murray DB, Gardner JD, Levick SP, Brower GL, Morgan LG, Janicki JS,. Response of cardiac mast cells to atrial natriuretic peptide. Am J Physiol Hear Circ Physiol 2007; 293: H1216-22.
76. Robinson JW, Lou X, Potter LR,. The indolocarbazole, Go6976, inhibits guanylyl cyclase-A and -B. Br J Pharmacol 2011; 164: 499-506.
77. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S, investigators JW. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-93.
78. Mentzer RM, Jr., Oz MC, Sladen RN, Graeve AH, Hebeler RF, Jr., Luber JM, Jr., Smedira NG, Investigators N,. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial. J Am Coll Cardiol 2007; 49: 716-26.
79. Sezai A, Wakui S, Akiyama K, Hata M, Yoshitake I, Unosawa S, Shiono M, Hirayama A,. Myocardial protective effect of human atrial natriuretic peptide in cardiac surgery. 'hANP shot' in clinical safety trial. Circ J 2011; 75: 2144-50.
80. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapil in heart failure. N Engl J Med 2014; 37: 993-1004.
81. Rehm M, Haller M, Orth V, Kreimeier U, Jacob M, Dressel H, Mayer S, Brechtelsbauer H, Finsterer U,. Changes in blood volume and hematocrit during acute preoperative volume loading with 5% albumin or 6% hetastarch solutions in patients before radical hysterectomy. Anesthesiology 2001; 95: 849-56.
82. Rehm M, Orth V, Kreimeier U, Thiel M, Haller M, Brechtelsbauer H, Finsterer U,. Changes in intravascular volume during acute normovolemic hemodilution and intraoperative retransfusion in patients with radical hysterectomy. Anesthesiology 2000; 92: 657-64.
83. Curry FR,. Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume. J Clin Invest 2005; 115: 1458-61.
84. Chappell D, Bruegger D, Potzel J, Jacob M, Vogeser M, Conzen P, Becker BF, Rehm M,. Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. Crit Care 2014; 18: 538.
85. Chappell D, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M,. A rational approach to perioperative fluid management. Anesthesiology 2008; 109: 723-40.
86. Jacob M, Chappell D, Hollmann MW,. Current aspects of perioperative fluid handling in vascular surgery. Curr Opin Anaesthesiol 2009; 22: 100-8.
87. McCarthy KJ, Wassenhove-McCarthy DJ,. The glomerular basement membrane as a model system to study the bioactivity of heparan sulphate glycosaminoglycans. Microsc Microanal 2012; 18: 3-21
88. Arkill KP, Knupp C, Michel CC, Neal CR, Qvortrup K, Rostgaard J, Squire JM,. Similar endothelial glycocalyx structures in microvessels from a range of mammalian tissues: evidence for a common filtering mechanism? Biophys J 2011; 101: 1046-56.
89. Haraldsson B, Nystrom J, Deen WM,. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008; 88: 451-487.
90. Jeansson M, Haraldsson B,. Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 2006; 290: F111-F116.
91. Friden V, Oveland E, Tenstad O, Ebefors K, Nyström J, Nilsson UA, Haraldsson B,. The glomerular endothelial cell coat is essential for glomerular filtration. Kidney Int 2011; 79: 1322-1330.
92. Adembri C, Sgambati E, Vitali L, Selmi V, Margheri M, Tani A, Bonaccini L, Nosi D, Caldini AL, Formigli L, De Gaudio AR,. Sepsis induces albuminuria and alterations in the glomerular filtration barrier: a morphofunctional study in the rat. Crit Care 2011; 15: R277.
93. Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE, Mathieson PW,. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 2007; 18: 2885-93.
94. Singh A, Friden V, Dasgupta I, Foster RR, Welsh GI, Tooke JE, Haraldsson B, Mathieson PW, Satchell SC,. High glucose causes dysfunction of the human glomerular endothelial glycocalyx. Am J Physiol Ren Physiol 2011; 300: F40-8.
95. Friden V, Oveland E, Tenstad O, Ebefors K, Nystrom J, Nilsson UA, Haraldsson B,. The glomerular endothelial cell coat is essential for glomerular filtration. Kid Int 2011; 79: 1322-30.
96. Vlahu CA, Lemkes BA, Struik DG, Koopman MG, Krediet RT, Vink H,. Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol 2012; 23: 1900-8.
97. Dane MJ, Khairoun M, Lee DH, van den Berg BM, Eskens BJ, Boels MG, van Teeffelen JW, Rops AL, van der Vlag J, van Zonneveld AJ, Reinders ME, Vink H, Rabelink TJ,. Association of kidney function with changes in the endothelial surface layer. Clin J Am Soc Nephrol 2014; 9: 698-704.
98. Korte S, Wiesinger A, Straeter AS, Peters W, Oberleithner H, Kusche-Vihrog K,. Firewall function of the endothelial glycocalyx in the regulation of sodium homeostasis. Pflugers Archiv: Eur J Physiol 2012; 463: 269-78.
99. Johansson PI, Sorensen AM, Perner A, Welling KL, Wanscher M, Larsen CF, Ostrowski SR,. High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality. J Thromb Haemost 2012; 10: 207-16.
100. Ostrowski SR, Sorensen AM, Windelov NA, Perner A, Welling KL, Wanscher M, Larsen CF, Johansson PI,. High levels of soluble VEGF receptor 1 early after trauma are associated with shock, sympathoadrenal activation, glycocalyx degradation and inflammation in severely injured patients: a prospective study. Scand J Traum Resusc Emerg Med 2012; 20: 27.
101. Ostrowski SR, Johansson PI,. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Traum Acute Care Surg 2012; 73: 60-6.
102. Trung DT, Wills B,. systemic vascular leakage associated with dengue infections-the clinical perspective. Curr Top Microbiol Immunol 2010; 338: 57-66.
103. Connolly-Andersen A-M, Thunberg T, Ahlm C,. Endothelial Activation and Repair During Hantavirus Infection: Association with Disease Outcome. Open Forum Infectious Diseases, Oxford University Press, 2014; 1: 1 ofu027.
104. Ozturk B, Kuscu F, Tutuncu E, Sencan I, Gurbuz Y, Tuzun H,. Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever. J Clin Virol 2010; 47: 115-9.
105. Marsac D, Garcia S, Fournet A, Aguirre A, Pino K, Ferres M, Kalergis AM, Lopez-Lastra M, Veas F,. Infection of human monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state, the secretion of active MMP-9 and indirectly enhances endothelial permeability. Virol J 2011; 8: 223.
106. Luplertlop N, Misse D,. MMP cellular responses to dengue virus infection-induced vascular leakage. Jap J Inf Dis 2008; 61: 298-301.
107. Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L, Bodelsson M,. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock 2008; 30: 623-7.
108. Steppan J, Hofer S, Funke B, Brenner T, Henrich M, Martin E, Weitz J, Hofmann U, Weigand MA,. Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalyx. J Surg Res 2011; 165: 136-41.
109. Sallisalmi M, Tenhunen J, Yang R, Oksala N, Pettila V,. Vascular adhesion protein-1 and syndecan-1 in septic shock. Acta Anaesth Scand 2012; 56: 316-22.
110. Yagmur E, Koch A, Haumann M, Kramann R, Trautwein C, Tacke F,. Hyaluronan serum concentrations are elevated in critically ill patients and associated with disease severity. Clin Biochem 2012; 45: 82-7.
111. Nieuwdorp M, Meuwese MC, Mooij HL, van Lieshout MH, Hayden A, Levi M, Meijers JC, Ince C, Kastelein JJ, Vink H, Stroes ES,. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 2009; 202: 296-303.
112. Delaney AP, Dan A, McCaffrey J, Finfer S,. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011; 39: 386-91.
113. Jacob M, Bruegger D, Rehm M, Welsch U, Conzen P, Becker BF,. Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability. Anesthesiology 2006; 104: 1223-31.
114. Jacob M, Paul O, Mehringer L, Chappell D, Rehm M, Welsch U, Kaczmarek I, Conzen P, Becker BF,. Albumin augmentation improves condition of guinea pig hearts after 4 hr of cold ischemia. Transplantation 2009; 87: 956-65.
115. Zausig YA, Chappell D, Becker BF, Potschka D, Busse H, Nixdorf K, Bitzinger D, Jacob B, Jacob M,. The impact of crystalloidal and colloidal infusion preparations on coronary vascular integrity, interstitial oedema and cardiac performance in isolated hearts. Crit Care 2013; 17: R203.
116. Oberleitner H., Two barriers for sodium in vascular endothelium? Ann Med 2012; 44: S143-8.
117. http://www.awmf.org/leitlinien/detail/ll/001-020.html
118. Oberleitner H., Vascular endothelium: a vulnerable transit zone for merciless sodium. Nephrol Dial Transplant 2014; 29: 240-6
119. Yang Y, Schmidt EP,. The endothelial glycocalyx: an important regulator of the pulmonary vascular barrier. Tissue barriers 2013; 1-14.
120. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH, Thompson KR, Geraci MW, Douglas IS, Pearse DB, Tuder RM,. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 2012; 18: 1217-23.
121. Schmidt EP, Li G, Li L, Fu L, Yang Y, Overdier KH, Douglas IS, Linhardt RJ,. The circulating glycosaminoglycan signature of respiratory failure in critically ill adults. J Biol Chem 2014; 289: 8194-202.
122. Nandi A, Estess P, Siegelman MH,. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem 2000; 275: 14939-48.
123. Donati A, Damiani E, Luchetti M, Domizi R, Scorcella C, Carsetti A, Gabbanelli V, Carletti P, Bencivenga R, Vink H, Adrario E, Piagnerelli M, Gabrielli A, Pelaia P, Ince C,. Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in patients with sepsis: a pilot study. Crit Care 2014; 18: R33.
124. Henry CB, Duling BR,. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol 1999; 277: H508-14.
125. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M,. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000; 148: 811-24.
126. Barbouri D, Afratis N, Gialeli C, Vynios DH, Theocharis AD, Karamanos NK,. Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol 2014; 4: 4.
127. Mulivor AW, Lipowsky HH,. Inhibition of glycan shedding and leukocyte-endothelial adhesion in postcapillary venules by suppression of matrixmetalloprotease activity with doxycycline. Microcirculation 2009; 16: 657-66.
128. Lipowsky HH, Sah R, Lescanic A,. Relative roles of doxycycline and cation chelation in endothelial glycan shedding and adhesion of leukocytes. Am J Physiol Heart Circ Physiol 2011; 300: H415-22.
129. Lipowsky HH, Lescanic A,. The effect of doxycycline on shedding of the glycocalyx due to reactive oxygen species. Microvasc Res 2013; 90: 80-5.
130. Ramnath R, Foster RR, Qiu Y, Cope G, Butler MJ, Salmon AH, Mathieson PW, Coward RJ, Welsh GI, Satchell SC,. Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor alpha: a contributor to endothelial cell glycocalyx dysfunction. FASEB J 2014; 3. pii: fj.14-252221. [Epub ahead of print].
131. Subramanian SV, Fitzgerald ML, Bernfield M,. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 1997; 272: 14713-20.
132. Schmidt A, Echtermeyer F, Alozie A, Brands K, Buddecke E,. Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds. J Biol Chem 2005; 280: 34441-6.
133. Chung MC, Jorgensen SC, Popova TG, Bailey CL, Popov SG,. Neutrophil elastase and syndecan shedding contribute to antithrombin depletion in murine anthrax. FEMS Immunol Med Microbiol 2008; 54: 309-18.
134. Annecke T, Chappell D, Chen C, Jacob M, Welsch U, Sommerhoff CP, Rehm M, Conzen PF, Becker BF,. Sevoflurane preserves the endothelial glycocalyx against ischaemia-reperfusion injury. Br J Anaesth 2010; 104: 414-21.
135. Chappell D, Jacob M, Hofmann-Kiefer K, Bruegger D, Rehm M, Conzen P, Welsch U, Becker BF,. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology 2007; 107: 776-84.
136. Uhl B, Zuchtriegel G, Puhr-Westerheide D, Praetner M, Rehberg M, Fabritius M, Hessenauer M, Holzer M, Khandoga A, Furst R, Zahler S, Krombach F, Reichel CA,. Tissue plasminogen activator promotes postischemic neutrophil recruitment via its proteolytic and nonproteolytic properties. Arterioscler Thromb Vas Biol 2014; 34: 1495-504.
137. Chappell D, Jacob M, Hofmann-Kiefer K, Rehm M, Welsch U, Conzen P, Becker BF,. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovas Res 2009; 83: 388-96.
138. Wang J, Wang Y, Wang J, Gao J, Tong C, Manithody C, Li J, Rezaie AR,. Antithrombin is protective against myocardial ischemia and reperfusion injury. J Thromb Haeost 2013; 11: 1020-8.
139. Meier HL, Heck LW, Schulman ES, MacGlashan DW, Jr., Purified human mast cells and basophils release human elastase and cathepsin G by an IgE-mediated mechanism. Int Arch Allerg Appl Immun 1985; 77: 179-83.
140. Winkler CW, Foster SC, Matsumoto SG, Preston MA, Xing R, Bebo BF, Banine F, Berny-Lang MA, Itakura A, McCarty OJ, Sherman LS,. Hyaluronan anchored to activated CD44 on central nervous system vascular endothelial cells promotes lymphocyte extravasation in experimental autoimmune encephalomyelitis. J Biol Chem 2012; 287: 33237-51.
141. Job KM, Dull RO, Hlady V,. Use of reflectance interference contrast microscopy to characterize the endothelial glycocalyx stiffness. Am J Physiol Lung Cell Molec Physiol 2012; 302: L1242-9.
142. Mitchell MJ, King MR,. Physical biology in cancer. 3. The role of cell glycocalyx in vascular transport of circulating tumor cells. Am J Physiol Cell Physiol 2014; 306: C89-97.
143. Stevens AP, Hlady V, Dull RO,. Fluorescence correlation spectroscopy can probe albumin dynamics inside lung endothelial glycocalyx. Am J Physiol Lung Cell Molecul Physiol 2007; 293: L328-35.
144. Zeng Y, Adamson RH, Curry FR, Tarbell JM,. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Hear Circ Physiol 2014; 306: H363-72.
145. Andreozzi GM,. Sulodexide in the treatment of chronic venous disease. Am J Cardiovascular Drugs: Drugs, Devices, and other interventions 2012; 12: 73-81.
146. Hoppensteadt DA, Fareed J,. Pharmacological profile of sulodexide. Int Angiol 2014; 33: 229-35.
147. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H,. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53: 2646-55.
148. Weiss R, Niecestro R, Raz I,. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007; 67: 2681-96.
149. Gaddi AV, Cicero AF, Gambaro G,. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. Int J Nephrol Renovasc Dis 2010; 3: 99-105.
150. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC, Collaborative Study G,. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23: 123-30.
151. Coccheri S., Biological and clinical effects of sulodexide in arterial disorders and diseases. Int Angiol 2014; 33: 263-74.
152. Coccheri S, Mannello F,. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther 2014; 8: 49-65.
153. Potter DR, Jiang J, Damiano ER,. The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro. Circ Res 2009; 104: 1318-25.
154. Dane MJ, van den Berg BM, Avramut MC, Faas FG, van der Vlag J, Rops AL, Ravelli RB, Koster BJ, van Zonneveld AJ, Vink H, Rabelink TJ,. Glomerular endothelial surface layer acts as a barrier against albumin filtration. Am J Pathol 2013; 182: 1532-40.
155. Giantsos-Adams KM, Koo AJ-A, Song S, Sakai J, Sankaran J, Shin JH, Garcia-Cardena G, Dewey CF Jr., Heparan sulphate regrowth profiles under laminar shear flow following enzymatic degradation. Cell Mol Bioeng 2013; 6: 160-74.